SCHEMBL5135685

SCHEMBL5135685

CCCCN(CCCCCC(=O)OC)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.52
C5AR1 P21730 1/20 0.41
HDAC1 Q13547 1/20 0.41
TP53 P04637 1/20 0.40
TSHR P16473 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
CYP3A4 P08684 2/20 0.39
GAA P10253 1/20 0.39
LTB4R Q15722 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
FPR2 P25090 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134972 0.94 FAAH (0.52) FAAHC5AR1HDAC1TP53TSHR
SCHEMBL650694 0.86 TSHR (0.51) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5135779 0.85 TSHR (0.44) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5072206 0.84 FAAH (0.42) FAAHC5AR1HDAC1TSHR
SCHEMBL5135950 0.81 LPAR1 (0.42) C5AR1HDAC1KDM4EALDH1A1GAA
SCHEMBL5135893 0.81 TLR7 (0.49) C5AR1
SCHEMBL650439 0.81 FAAH (0.48) FAAHTSHRKDM4EALDH1A1HPGD
SCHEMBL649161 0.80 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL649871 0.79 C5AR1 (0.42) FAAHC5AR1HDAC1KDM4EHPGD
SCHEMBL1913014 0.79 C5AR1 (0.42) FAAHC5AR1HDAC1TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed